AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland

Rhea-AI Summary

AIM ImmunoTech (NYSE American: AIM) presented the latest progress of its lead drug candidate Ampligen for pancreatic cancer treatment at the 5th Annual Marie Skłodowska-Curie Symposium in Poland. The presentation highlighted positive data from both the Phase 2 DURIPANC clinical trial and an Early Access Program, focusing on Progression-Free Survival and Overall Survival metrics.

The company's ongoing Phase 2 DURIPANC study evaluates Ampligen in combination with AstraZeneca's durvalumab for treating late-stage metastatic pancreatic cancer. Notably, Ampligen has secured patent protection through 2039 and holds both US and EU orphan drug designations for market protection upon approval.

Latest progress from lead program Ampligen for the treatment of pancreatic cancer highlighted at the International 5^th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025); Presentation now available here

Ampligen has demonstrated data-driven promise in Progression-Free Survival and Overall Survival in both the DURIPANC clinical trial and an Early Access Program

OCALA, Fla., Sept. 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the presentation on the latest positive progress from its Ampligen clinical program in pancreatic cancer at the 5^th Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care hosted by and at Poland’s National Institute of Oncology in Warsaw, Poland.

AIM CEO Thomas K. Equels provided an overview of data from AIM’s pancreatic cancer Early Access Program and the latest advancements in the Phase 2 DURIPANC pancreatic cancer clinical trial currently underway at Erasmus University Medical Center in the Netherlands. The slides accompanying the presentation are now available on the Company’s website.

“Ampligen continues to demonstrate its potential for the treatment of late-stage metastatic and locally advanced pancreatic cancer. Our growing body of positive data continues to bolster our confidence. This lethal malignancy is a high unmet need. In particular, the Progression-Free Survival and Overall Survival – which are the gold standards for drug approval – seen in the clinical data demonstrated to date underscore our strong belief in the potential,” AIM ImmunoTech CEO Thomas K. Equels stated. “I am pleased to be a part of this gathering of global regulatory leaders, world-renowned oncologists and biopharma industry to share this important progress with Ampligen and highlight its potential in late-stage pancreatic cancer. We look forward to advancing its development and remain committed to bringing it to patients in desperate need and without real hope.”

AIM’s drug Ampligen is currently being tested in an ongoing Phase 2 DURIPANC clinical study evaluating the combination therapy of Ampligen and AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor durvalumab in the treatment of late-stage metastatic pancreatic cancer patients (See: ClinicalTrials.gov NCT05927142). Ampligen has patent protection for such a combination therapy in the United States through 2039, and US and EU orphan drug designations that will grant market protections for an approved drug.

For more information on Ampligen and to stay up to date with the latest advancements, please visit the Company’s website, aimimmuno.com.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen^® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

Cautionary Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a therapy in pancreatic cancer. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5084607c-f35a-48da-8b06-10fa35de54ff

Investor Contact:

JTC Team, LLC
Jenene Thomas
908.824.0775
AIM@jtcir.com

FAQ

What is AIM ImmunoTech's (AIM) main drug candidate for pancreatic cancer?

AIM ImmunoTech's main drug candidate is Ampligen, which is being tested in combination with AstraZeneca's durvalumab for late-stage metastatic pancreatic cancer treatment.

What are the key findings from AIM's pancreatic cancer clinical trials?

The clinical trials have shown promising data in Progression-Free Survival and Overall Survival metrics from both the DURIPANC clinical trial and Early Access Program.

What regulatory protections does AIM's Ampligen have?

Ampligen has patent protection through 2039 for combination therapy in the United States, plus US and EU orphan drug designations for market protection upon approval.

Which clinical trial is currently ongoing for AIM's Ampligen?

The Phase 2 DURIPANC clinical trial (NCT05927142) is currently ongoing at Erasmus University Medical Center, testing Ampligen in combination with AstraZeneca's durvalumab for late-stage metastatic pancreatic cancer.

Where did AIM ImmunoTech present their latest Ampligen data in 2025?

AIM presented at the 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care at Poland's National Institute of Oncology in Warsaw.